• SPX
  • $5,762.48
  • 0.42 %
  • $24.31
  • DJI
  • $42,330.15
  • 0.04 %
  • $17.15
  • N225
  • $38,632.85
  • 1.88 %
  • $713.37
  • FTSE
  • $8,236.95
  • -1.01 %
  • -$83.81
  • IXIC
  • $18,189.17
  • 0.38 %
  • $69.58
Atara Biotherapeutics, Inc. (ATRA) Stock Price, News & Analysis

Atara Biotherapeutics, Inc. (ATRA) Stock Price, News & Analysis

Currency in USD Disclaimer

$8.13

$0.06

(0.68%)

Day's range
$8.01
Day's range
$8.66
50-day range
$6.5
Day's range
$11.31
  • Country: US
  • ISIN: US0465131078
52 wk range
$4.98
Day's range
$45.75
  • CEO: Dr. Pascal Touchon D.V.M.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -29.01
  • Piotroski Score 4.00
  • Grade Outperform
  • Symbol (ATRA)
  • Company Atara Biotherapeutics, Inc.
  • Price $8.13
  • Changes Percentage (0.68%)
  • Change $0.06
  • Day Low $8.01
  • Day High $8.66
  • Year High $45.75

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/29/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $10.50
  • High Stock Price Target $18.00
  • Low Stock Price Target $3.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.12
  • Trailing P/E Ratio -0.25
  • Forward P/E Ratio -0.25
  • P/E Growth -0.25
  • Net Income $-2,761,260,000

Income Statement

Quarterly

Annual

Latest News of ATRA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.